Do you think they are likely to layoff a good portion of the sales force who promotes Humira in 2023 once it goes generic? Or will Skyrizi be enough to keep everyone around
Don’t be surprised if Abbvie stops paying for performance on Humira. Biosimilars will take over after this study!
https://accessiblemeds.org/resource...biosimilar-savings-totaled-record-338-billion
what do you mean yes and yes. Yes there will be layoffs? Or yes there will be enough work around with Skyrizi for most people to stay? And if a layoff ensues will your kids still be singing the Skyrizi song
Tell us more about softening the blow. Asking for a friend.If you do the math, Skyrizi can help soften the blow a little bit. Rinvoq growth will be nowhere near what was originally thought (thank Pfizer and the FDA for that one). It's highly unlikely their combined sales cover even half of what we will lose.
If you do the math, Skyrizi can help soften the blow a little bit. Rinvoq growth will be nowhere near what was originally thought (thank Pfizer and the FDA for that one). It's highly unlikely their combined sales cover even half of what we will lose.
AbbVie confident of blockbuster drug replacements, lifts profit view third timeIf you do the math, Skyrizi can help soften the blow a little bit. Rinvoq growth will be nowhere near what was originally thought (thank Pfizer and the FDA for that one). It's highly unlikely their combined sales cover even half of what we will lose.
